litlas
Log inCreate account

Tadeusz Robak

Active 1998–2025

163
Papers
26,277
Citations
79
h-index
157
i10-index

Citations

Citations per year for Tadeusz Robak1979: 1 citations1999: 2 citations2000: 1 citations2001: 8 citations2002: 6 citations2003: 8 citations2004: 14 citations2005: 13 citations2006: 27 citations2007: 46 citations2008: 71 citations2009: 93 citations2010: 107 citations2011: 120 citations2012: 157 citations2013: 123 citations2014: 143 citations2015: 200 citations2016: 159 citations2017: 192 citations2018: 231 citations2019: 786 citations2020: 958 citations2021: 966 citations2022: 726 citations2023: 578 citations2024: 1,089 citations2025: 470 citations2026: 18 citations1980–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,256 citing papers, 24.1% of this breakdownItaly: 655 citing papers, 7% of this breakdownGermany: 631 citing papers, 6.7% of this breakdownUnited Kingdom: 609 citing papers, 6.5% of this breakdownChina: 556 citing papers, 5.9% of this breakdownFrance: 459 citing papers, 4.9% of this breakdownSpain: 369 citing papers, 3.9% of this breakdownAustralia: 362 citing papers, 3.9% of this breakdownCanada: 269 citing papers, 2.9% of this breakdownNetherlands: 267 citing papers, 2.9% of this breakdownPoland: 250 citing papers, 2.7% of this breakdownSwitzerland: 218 citing papers, 2.3% of this breakdown
0%24.1%Other 26.3%

Institutions

Fields

  • Medicine78.7%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Immunology and Microbiology4.3%
  • Materials Science0.8%
  • Chemistry0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Other1.2%

Topics

  • Chronic Lymphocytic Leukemia Research14%
  • Lymphoma Diagnosis and Treatment10.1%
  • Chronic Myeloid Leukemia Treatments4.1%
  • Acute Myeloid Leukemia Research3.7%
  • Immunodeficiency and Autoimmune Disorders3.4%
  • Multiple Myeloma Research and Treatments3.4%
  • Other61.3%

Coauthors

All papers

Open in search
  1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 cited by 1,689

  2. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

    Authors: John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Mustafa Nuri Yenerel, Árpád Illés, Neil E. Kay, José A. García‐Marco, Anthony R. Mato, Javier Pinilla‐Ibarz, John F. Seymour, Stéphane Leprêtre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak - Journal of Clinical Oncology 2021 cited by 635

  3. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan O’Brien, Constantine S. Tam, Lugui Qiu, Keshu Zhou, Martin Šimkovič, Jiřı́ Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte Yimer, Tommi Salmi, Megan-Der-Yu Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman - New England Journal of Medicine 2022 cited by 457

  4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  5. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, John F. Gerecitano, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A. Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P. Kater - New England Journal of Medicine 2018 cited by 909

  6. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    Authors: Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepłuch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen - The Lancet Oncology 2022 cited by 278

  7. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    Authors: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 cited by 269

  8. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

    Authors: Arnon P. Kater, Carolyn Owen, Carol Moreno, George Follows, Talha Munir, Mark‐David Levin, Ohad Benjamini, Ann Janssens, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Don A. Stevens, Sergey Voloshin, Vladimir Vorobyev, Loïc Ysebaert, Rui Qin, Andrew J. Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann - NEJM Evidence 2022 cited by 226

  9. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    Authors: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 cited by 1,617

  10. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    Authors: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater - Blood 2022 cited by 151

  11. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Authors: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 cited by 463

  12. Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

    Authors: Carsten Utoft Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark‐David Levin, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir Vorobyev, Münci Yağcı, Loïc Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P. Kater - The Lancet Oncology 2023 cited by 139

  13. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

    Authors: Michael Wang, Simon Rule, Pier Luigi Zinzani, André Goy, Olivier Casasnovas, Stephen D. Smith, Gandhi Damaj, Jeanette K. Doorduijn, T. Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric D. Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Obéric, Tadeusz Robak, Todd Covey, Richa Dua, Ahmed Hamdy, Xin Huang, Raquel Izumi, Priti Patel, Wayne Rothbaum, J. Greg Slatter, Wojciech Jurczak - The Lancet 2017 cited by 448

  14. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

    Authors: Arnon P. Kater, Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Julie Dubois, Eric Eldering, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Su Young Kim, Brenda Chyla, Elizabeth A. Punnoose, Christopher R. Bolen, Zoe J. Assaf, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, John F. Seymour - Journal of Clinical Oncology 2020 cited by 220

  15. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Authors: Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, Pierre DesJardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser - Leukemia 2018 cited by 489

  16. Drug resistance in multiple myeloma

    Authors: Paweł Robak, Izabela Dróźdż, Janusz Szemraj, Tadeusz Robak - Cancer Treatment Reviews 2018 cited by 290

  17. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

    Authors: Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan O’Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Keshu Zhou, Martin Šimkovič, Jiřı́ Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte Yimer, Tommi Salmi, Meng Ji, Jessica L. Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak - Journal of Clinical Oncology 2022 cited by 93

  18. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

    Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin, Tadeusz Robak, Douglas E. Gladstone, Philipp le Coutre, Sascha Dietrich, Mirjana Gotić, Loree Larratt, Fritz Offner, Gary J. Schiller, Ronan Swords, Larry Bacon, Monica Bocchia, Krimo Bouabdallah, Dimitri Breems, Agostino Cortelezzi, Shira Dinner, Michael Doubek, Bjørn Tore Gjertsen, Marco Gobbi, Andrzej Hellmann, Stéphane Leprêtre, Frédéric Maloisel, Farhad Ravandi, Philippe Rousselot, Mathias Rummel, Tanya Siddiqi, Tamar Tadmor, Xavier Troussard, Cecilia Arana Yi, Giuseppe Saglio, Gail J. Roboz, Kemal Balic, Nathan Standifer, Peng He, Shannon Marshall, Wyndham H. Wilson, Ira Pastan, Nai-Shun Yao, Francis J. Giles - Leukemia 2018 cited by 247

  19. Safety and Tolerability of Antibody-Drug Conjugates in Cancer

    Authors: Anna Wolska, Tadeusz Robak - Drug Safety 2019 cited by 117

  20. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

    Authors: Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kießling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, James B. Bussel, Stephen Jolles - Blood Advances 2020 cited by 110

  21. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

    Authors: Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepłuch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, Jennifer R. Brown - Haematologica 2020 cited by 103

  22. Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

    Authors: Sean Whittaker, Marie‐France Demierre, Ellen J. Kim, Alain H. Rook, Adam Lerner, Madeleine Duvic, Julia Scarisbrick, Sunil Reddy, Tadeusz Robak, Jürgen C. Becker, А. В. Самцов, William McCulloch, Youn H. Kim - Journal of Clinical Oncology 2010 cited by 661

  23. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Authors: Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Michele Baccarani, M B Agarwal, María Soledad Undurraga, Jianxiang Wang, Juan Julio Kassack Ipiña, Dong‐Wook Kim, Michinori Ogura, Carolina Pavlovsky, Christian Junghanß, Jorge Milone, Franck E. Nicolini, Tadeusz Robak, Jan Van Droogenbroeck, Edo Vellenga, M. Brigid Bradley‐Garelik, Chao Zhu, Andreas Hochhaus - Blood 2011 cited by 605

  24. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

    Authors: Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter‐Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd‐Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko‐Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska‐Zubkiewicz, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar Lahoud, Jeffrey A. Zonder, Kent A. Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej Jakubowiak - The Lancet Oncology 2023 cited by 74